Skip to content
Esta página está disponible en españolCambiar →
GestorLensSign up

Karyopharm Therapeutics (KPTI): which funds own it

Health Care →(by SIC code, unreviewed)Data as of Jun 30, 2026 (Q2 2026) · updated on Nov 5, 2026

A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.

Follow KPTI for free
Share

Sections with a free account

5 concentrated managers hold it (−2 vs last quarter) with a median weight of 0.2%.

Who owns Karyopharm Therapeutics?

Holders that filed a Schedule 13D or 13G with the SEC for owning more than 5% of the shares: RA Capital Management (13G/A filed Aug 14, 2026), Affinity Asset Advisors (13G/A filed May 14, 2026), Adage Capital Management (13G/A filed Aug 12, 2026), T. Rowe Price Investment Management (13G/A filed Jun 5, 2026) and Goldman Sachs Group (13G/A filed Aug 11, 2026). As of Jun 30, 2026, the largest holders reported on Form 13F were RA Capital Management (1.9 million shares), Adage Capital Partners Gp, L.l.c (1.5 million shares) and Acorn Capital Advisors (1.5 million shares).

Which institutions hold the most Karyopharm Therapeutics shares?

Per Form 13F filings as of Jun 30, 2026:

  1. 1. RA Capital Management: 1.9 million shares
  2. 2. Adage Capital Partners Gp, L.l.c: 1.5 million shares
  3. 3. Acorn Capital Advisors: 1.5 million shares
  4. 4. Goldman Sachs Group: 1.4 million shares
  5. 5. BlackRock: 1.4 million shares
  6. 6. Vanguard Capital Management: 958,979 shares
  7. 7. Catalio Capital Management: 940,855 shares
  8. 8. Avidity Partners Management: 924,487 shares
  9. 9. T. Rowe Price Investment Management: 786,309 shares
  10. 10. Two Sigma Investments: 695,264 shares

Sources:13G/A by RA Capital Management (Aug 14, 2026) ↗13G/A by Affinity Asset Advisors (May 14, 2026) ↗13G/A by Adage Capital Management (Aug 12, 2026) ↗13G/A by T. Rowe Price Investment Management (Jun 5, 2026) ↗13G/A by Goldman Sachs Group (Aug 11, 2026) ↗All of the company's proxy statements on EDGAR ↗

We hold 13D and 13G filings made since Dec 23, 2024: a holder above 5% that has not filed since then does not appear here.

Karyopharm Therapeutics revenue

Karyopharm Therapeutics reported annual revenue of $146.1 million for fiscal year 2025 (year ended December 31, 2025), according to its Form 10-K filed with the SEC (XBRL data).

Concentrated managers
5
All 13F: 95
Consensus
0/100
across 5 concentrated managersRanks by accumulation, portfolio weight and number of managers; it does not say more are buying than selling.
Price at Jun 30, 2026 (per 13F)
$9.77
+75.4% in the quarter · reported value ÷ shares, not the quote · See current quote ↗

Quarter flow (concentrated managers)

Change in managers (7 → 5): 1 opened · 3 exited = −2

Net flow in the quarter: −$17.1M (−1.8 M shares) · bought $2.9M and sold $20.0MShares concentrated managers added minus those they cut, valued at the 13F quarter-end implied price, not each trade's price. It is a different measure from the change in managers: the two can have opposite signs.

Concentrated managers holding it

Up to 15, sorted by position value. The percentage is the weight in each manager's portfolio.

Largest holders of KPTI (all 13F filers)

The 10 13F filers with the most shares as of Jun 30, 2026, whatever their type (index firms usually come first). “Change”: shares added or cut versus the previous quarter, split-adjusted; “no data” = there is no comparable portfolio for the previous quarter (no filing, or a filing with its holdings under confidential treatment). “% of the company” only where shares outstanding are up to date. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. With a free account: the top 25, the largest buyers and the largest sellers.

Fundamentals

12-month figures to Jun 30, 2026 · balance sheet as of Jun 30, 2026.

Profitability
Operating margin
-56.2%
Net margin
—
ROE
—
Growth
Revenue (TTM)
$147M
Revenue growth
6.8%
Net income (TTM)
$-225M
Balance sheet
Net debt / EBITDA
—
Free cash flow (TTM)
—
Quality vs sector
—

This company's sector comes from its SIC code, unreviewed, or has too few comparable companies: we do not compare it with its sector.

Figures from the statements the company filed with the SEC (10-K, 10-Q). Free cash flow = operating cash flow − capital expenditures; empty if the company does not report capex. “Quality vs sector”: 0 to 100, the average of its percentiles in ROE, operating margin, free-cash-flow margin, revenue and earnings growth and net debt / EBITDA (at least 3 needed) against companies in its sector above $300M. How each figure is calculated

Shares outstanding: buybacks and dilution

Diluted shares by fiscal year (split-adjusted)

2025: 11 K

75.2 M0
20202025

There is a jump that may be an undetected split: we do not show the changes.

Buybacks (FY 2025)
no data
Share issuance
no data
Stock-based compensation
$14.1M9.6% of revenue
Dividends paid
no data

From the statements the company filed with the SEC (10-K). The change compares average diluted shares of each fiscal year, on today's basis: negative = it bought back more than it issued; positive = dilution. “No data” = the company does not report that item under a tag we can read; it does not mean zero.

Earnings quality and debt

Operating cash flow ÷ net income (12 months)
no datanot calculated with negative net income
Interest coverage (operating income ÷ interest)
−2.0 timesnegative operating income
Debt due within 12 months
$40.3M0.62 times cash and investments

From the figures the company filed with the SEC. Cash flow over net income near or above 1 means earnings are collected in cash; far below, that part is accounting. Coverage says how many times operating income pays the latest fiscal year's interest. Maturities come from the debt note of the latest annual report, counted from its closing date. “No data” never means zero.

Insiders (Form 4)

Officers and directors who bought (6 m)
0
Amount (6 m)
$0
CEO/CFO bought (12 m)
No

10% owners who bought (6 m): 0

Open-market purchases, excluding 10b5-1 plans. Officers and directors only; joint filers of the same purchase count as one. 10% owners with no role are shown separately. 0 = nobody bought; “no data” = we do not have its Form 4 filings.

Each of the company's Form 4 filings, on EDGAR ↗Latest trades, with date and filing →

Above 5% (13D/13G)

Disclosed stakes, with their amendments. A filing is not always a purchase: there are also reductions and changes of filing entity.

This list may be incomplete: we hold 13D and 13G filings made since Dec 23, 2024. A holder above 5% that has not filed anything since then is not shown here.

  • Integrated Core Strategies (US)0.2%(fell below 5%)13G · amendmentfiling ↗Event: Sep 30, 2026 · filed: Oct 28, 2026
  • Anders Hove4.5%(fell below 5%)13G · amendmentfiling ↗Event: Oct 2, 2026 · filed: Oct 8, 2026
  • Anders Hove5.7%13G · amendmentfiling ↗Event: Sep 22, 2026 · filed: Sep 25, 2026

Above 5% over time (13D/13G)

Each holder with its filings in order. History since December 2024.

Flagged material events (8-K)

  • Nov 3, 2026Seriousfiling ↗

    Bankruptcy or receivership (Item 1.03)

    «In the United States Bankruptcy Court»

  • Nov 3, 2026Mediumfiling ↗

    Event that accelerates or increases a debt obligation (Item 2.04)

    «In the United States Bankruptcy Court»

  • Sep 11, 2026Mediumfiling ↗

    Event that accelerates or increases a debt obligation (Item 2.04)

  • Sep 11, 2026Routinefiling ↗

    Unregistered sale of equity securities (Item 3.02)

  • Jul 17, 2026Routinefiling ↗

    Change in directors or officers (Item 5.02)

  • May 28, 2026Routinefiling ↗

    Change in directors or officers (Item 5.02)

  • Mar 24, 2026Routinefiling ↗

    Unregistered sale of equity securities (Item 3.02)

    «Karyopharm’s Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction»

Alert items the company itself flagged in its 8-K filings with the SEC, most serious first. It is the form's label, with no interpretation from us: Item 5.02 covers routine appointments as well as a chief executive's departure; open the filing. The quoted headline is the original press release's.

All material events (8-K)

Earnings, agreements, financing, management changes and announcements from the last year, with a filter by type and a link to each filing.

Other Health Care stocks in managers' portfolios

Same sector and a similar number of concentrated managers holding them. It is a list to keep exploring, not a recommendation.

All of Health Care →

Follow KPTI for free

If someone reports a 5%+ stake, we email you (if you turn it on). And when you come back, see whether concentrated managers got in or out. No credit card.

Follow KPTI